| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 25 | 2025 | 946 | 3.320 |
Why?
|
| Lipoprotein(a) | 10 | 2025 | 140 | 2.670 |
Why?
|
| Lipoproteins | 9 | 2022 | 183 | 1.790 |
Why?
|
| Cholesterol, LDL | 13 | 2022 | 612 | 1.710 |
Why?
|
| Coronary Disease | 14 | 2023 | 638 | 1.640 |
Why?
|
| Cardiovascular Diseases | 18 | 2023 | 2088 | 1.590 |
Why?
|
| Triglycerides | 10 | 2022 | 605 | 1.550 |
Why?
|
| C-Reactive Protein | 12 | 2025 | 459 | 1.340 |
Why?
|
| Biomarkers | 39 | 2025 | 3415 | 1.000 |
Why?
|
| Troponin T | 15 | 2024 | 255 | 0.970 |
Why?
|
| Stroke | 11 | 2023 | 1049 | 0.960 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 8 | 2019 | 89 | 0.880 |
Why?
|
| Cholesterol | 7 | 2018 | 541 | 0.870 |
Why?
|
| Brain Ischemia | 4 | 2023 | 261 | 0.850 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 893 | 0.840 |
Why?
|
| Lipoproteins, LDL | 4 | 2019 | 118 | 0.740 |
Why?
|
| Risk Factors | 40 | 2025 | 10998 | 0.730 |
Why?
|
| Prospective Studies | 28 | 2024 | 6522 | 0.670 |
Why?
|
| Heart Failure | 12 | 2023 | 2315 | 0.670 |
Why?
|
| Prediabetic State | 2 | 2018 | 66 | 0.660 |
Why?
|
| Apolipoprotein C-III | 3 | 2022 | 46 | 0.640 |
Why?
|
| Middle Aged | 58 | 2025 | 28911 | 0.620 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 194 | 0.590 |
Why?
|
| Inflammation | 7 | 2021 | 1500 | 0.580 |
Why?
|
| Apolipoproteins E | 2 | 2018 | 188 | 0.570 |
Why?
|
| Aged | 38 | 2025 | 21279 | 0.540 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2023 | 326 | 0.480 |
Why?
|
| Hypertension | 2 | 2022 | 1362 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2019 | 744 | 0.470 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 132 | 0.470 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 62 | 0.460 |
Why?
|
| Incidence | 16 | 2025 | 3352 | 0.450 |
Why?
|
| Risk Assessment | 15 | 2021 | 3708 | 0.440 |
Why?
|
| Metabolic Syndrome | 7 | 2016 | 363 | 0.430 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 97 | 0.420 |
Why?
|
| Female | 62 | 2025 | 71316 | 0.410 |
Why?
|
| Male | 63 | 2025 | 65357 | 0.400 |
Why?
|
| Humans | 79 | 2025 | 131967 | 0.390 |
Why?
|
| Apolipoproteins B | 4 | 2019 | 144 | 0.380 |
Why?
|
| Troponin I | 3 | 2024 | 123 | 0.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2015 | 1413 | 0.360 |
Why?
|
| Peptide Fragments | 7 | 2023 | 782 | 0.360 |
Why?
|
| Proportional Hazards Models | 10 | 2019 | 1406 | 0.350 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2010 | 167 | 0.350 |
Why?
|
| Phospholipases A | 3 | 2005 | 30 | 0.330 |
Why?
|
| Population Surveillance | 2 | 2021 | 397 | 0.330 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 122 | 0.330 |
Why?
|
| Spouse Abuse | 1 | 2010 | 15 | 0.330 |
Why?
|
| Apolipoproteins | 3 | 2012 | 70 | 0.330 |
Why?
|
| Cholesterol, HDL | 7 | 2014 | 394 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 62 | 0.310 |
Why?
|
| Atrial Fibrillation | 3 | 2024 | 734 | 0.310 |
Why?
|
| Models, Psychological | 1 | 2010 | 141 | 0.300 |
Why?
|
| Carotid Arteries | 1 | 2010 | 126 | 0.300 |
Why?
|
| Blood Pressure | 6 | 2024 | 1345 | 0.300 |
Why?
|
| Chemokine CCL2 | 4 | 2018 | 114 | 0.290 |
Why?
|
| Monocytes | 3 | 2019 | 337 | 0.260 |
Why?
|
| Models, Biological | 2 | 2010 | 1396 | 0.260 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 246 | 0.260 |
Why?
|
| Obesity | 7 | 2016 | 2392 | 0.250 |
Why?
|
| United States | 20 | 2021 | 11827 | 0.250 |
Why?
|
| Adiponectin | 4 | 2018 | 124 | 0.240 |
Why?
|
| Weight Loss | 5 | 2015 | 530 | 0.240 |
Why?
|
| Coronary Artery Disease | 4 | 2014 | 870 | 0.240 |
Why?
|
| Postprandial Period | 2 | 2016 | 86 | 0.230 |
Why?
|
| Hospitalization | 7 | 2019 | 1942 | 0.220 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 74 | 0.220 |
Why?
|
| Prognosis | 10 | 2023 | 4961 | 0.210 |
Why?
|
| Albuminuria | 2 | 2022 | 106 | 0.210 |
Why?
|
| Dioxygenases | 1 | 2024 | 72 | 0.200 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 1002 | 0.200 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 2308 | 0.200 |
Why?
|
| Sirolimus | 2 | 2002 | 231 | 0.200 |
Why?
|
| Lipids | 5 | 2014 | 567 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 83 | 0.190 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 15 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6922 | 0.180 |
Why?
|
| Galectin 3 | 1 | 2021 | 31 | 0.170 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 22 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 666 | 0.170 |
Why?
|
| Peripheral Arterial Disease | 2 | 2016 | 315 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 602 | 0.160 |
Why?
|
| Cohort Studies | 11 | 2018 | 5122 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 105 | 0.160 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 9 | 0.160 |
Why?
|
| Life Style | 3 | 2018 | 445 | 0.160 |
Why?
|
| Time Factors | 8 | 2021 | 6285 | 0.160 |
Why?
|
| Diet, Western | 1 | 2019 | 20 | 0.160 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 32 | 0.150 |
Why?
|
| Blood Glucose | 4 | 2018 | 1104 | 0.150 |
Why?
|
| Linear Models | 4 | 2017 | 695 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2024 | 781 | 0.150 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 572 | 0.150 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3453 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 3928 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2010 | 39 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 404 | 0.140 |
Why?
|
| Interleukin-18 | 2 | 2023 | 78 | 0.140 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 32 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Protein Precursors | 2 | 2021 | 147 | 0.140 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 5298 | 0.130 |
Why?
|
| Risk | 5 | 2018 | 739 | 0.130 |
Why?
|
| Adipokines | 1 | 2018 | 121 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 542 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2019 | 377 | 0.130 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 97 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2863 | 0.130 |
Why?
|
| Interleukin-6 | 4 | 2024 | 419 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 372 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 876 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 209 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 27 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2021 | 770 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1964 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 792 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 2148 | 0.110 |
Why?
|
| White Matter | 1 | 2017 | 231 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 67 | 0.110 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 32 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 228 | 0.110 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2014 | 49 | 0.110 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 518 | 0.110 |
Why?
|
| Subtilisins | 1 | 2014 | 11 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 290 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 79 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 355 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 148 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1618 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 3843 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 156 | 0.100 |
Why?
|
| Athletes | 1 | 2014 | 72 | 0.100 |
Why?
|
| Particle Size | 1 | 2014 | 137 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2014 | 148 | 0.100 |
Why?
|
| Cognition | 1 | 2019 | 845 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 2697 | 0.100 |
Why?
|
| Exome | 1 | 2018 | 1076 | 0.100 |
Why?
|
| Brain Infarction | 1 | 2013 | 28 | 0.100 |
Why?
|
| Adult | 10 | 2022 | 31734 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 633 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 63 | 0.090 |
Why?
|
| Calcinosis | 2 | 2014 | 187 | 0.090 |
Why?
|
| Brain | 3 | 2024 | 3247 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2015 | 247 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2016 | 531 | 0.090 |
Why?
|
| Phospholipases A2 | 3 | 2006 | 30 | 0.090 |
Why?
|
| Overweight | 1 | 2015 | 378 | 0.090 |
Why?
|
| Carotid Artery, Internal | 2 | 2010 | 56 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 1838 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 732 | 0.090 |
Why?
|
| Apolipoprotein B-100 | 2 | 2001 | 36 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 347 | 0.090 |
Why?
|
| Apolipoproteins A | 2 | 2001 | 53 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 234 | 0.090 |
Why?
|
| Sex Factors | 4 | 2017 | 1352 | 0.090 |
Why?
|
| Carotid Stenosis | 2 | 2010 | 107 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3095 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2014 | 1695 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2019 | 832 | 0.080 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 10 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 53 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2011 | 495 | 0.080 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 42 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 60 | 0.080 |
Why?
|
| Body Weight | 1 | 2014 | 990 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 1713 | 0.080 |
Why?
|
| Prolactin | 1 | 2010 | 112 | 0.080 |
Why?
|
| Dehydroepiandrosterone | 1 | 2010 | 34 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 72 | 0.080 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 146 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 565 | 0.080 |
Why?
|
| Immunoassay | 3 | 2005 | 133 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2010 | 224 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 432 | 0.080 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 100 | 0.080 |
Why?
|
| Women's Health | 1 | 2010 | 143 | 0.070 |
Why?
|
| Dementia | 1 | 2014 | 435 | 0.070 |
Why?
|
| Postmenopause | 2 | 2020 | 149 | 0.070 |
Why?
|
| Age Factors | 4 | 2018 | 2869 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 955 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 421 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Liver | 2 | 2011 | 1802 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 3425 | 0.070 |
Why?
|
| Echocardiography | 2 | 2024 | 1138 | 0.070 |
Why?
|
| Phenotype | 2 | 2014 | 4531 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2014 | 1566 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2014 | 1236 | 0.060 |
Why?
|
| Comorbidity | 3 | 2017 | 1607 | 0.060 |
Why?
|
| Health Promotion | 1 | 2010 | 408 | 0.060 |
Why?
|
| Cytokines | 2 | 2010 | 1354 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1840 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2006 | 114 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 850 | 0.060 |
Why?
|
| Leptin | 3 | 2018 | 219 | 0.060 |
Why?
|
| Cystatin C | 2 | 2016 | 71 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 228 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2001 | 291 | 0.050 |
Why?
|
| Caveolins | 1 | 2003 | 14 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 110 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 255 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 63 | 0.050 |
Why?
|
| Simvastatin | 2 | 2013 | 75 | 0.050 |
Why?
|
| Ezetimibe | 2 | 2013 | 94 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 679 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 293 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 156 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 236 | 0.050 |
Why?
|
| Models, Cardiovascular | 2 | 2000 | 170 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2006 | 810 | 0.040 |
Why?
|
| Lipoproteins, VLDL | 1 | 2001 | 53 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1406 | 0.040 |
Why?
|
| Energy Intake | 1 | 2004 | 502 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 53 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6200 | 0.040 |
Why?
|
| tau Proteins | 1 | 2024 | 257 | 0.040 |
Why?
|
| India | 1 | 2001 | 245 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2001 | 244 | 0.040 |
Why?
|
| Smoking | 2 | 2016 | 928 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 421 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 189 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1519 | 0.040 |
Why?
|
| Insulin | 3 | 2014 | 1154 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 52 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1028 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 230 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.040 |
Why?
|
| Memory, Episodic | 1 | 2017 | 29 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 46 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2000 | 614 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 153 | 0.030 |
Why?
|
| Factor VIII | 1 | 2017 | 51 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 1255 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 249 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1078 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2017 | 166 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 512 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 79 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 192 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 570 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 261 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 998 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1419 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 293 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 175 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2015 | 89 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 388 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 18 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 1269 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 36 | 0.030 |
Why?
|
| Lipocalins | 1 | 2014 | 32 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 260 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 895 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 45 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 243 | 0.030 |
Why?
|
| Football | 1 | 2014 | 36 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 50 | 0.030 |
Why?
|
| Sitosterols | 1 | 2013 | 10 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1996 | 349 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 42 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 94 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 110 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 190 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 772 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 83 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 39 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 59 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1069 | 0.020 |
Why?
|
| Biological Assay | 1 | 2014 | 108 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2015 | 175 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 169 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2014 | 157 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2013 | 136 | 0.020 |
Why?
|
| Reference Values | 1 | 2014 | 692 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 303 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 643 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 741 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 750 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2014 | 457 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2154 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 49 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 37 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1457 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 80 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 296 | 0.020 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 195 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1996 | 1025 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 471 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2011 | 106 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 18504 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 1712 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 445 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2963 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 835 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2005 | 17703 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1638 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2011 | 264 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 876 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 1043 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 218 | 0.020 |
Why?
|
| Phantoms, Imaging | 2 | 2000 | 149 | 0.020 |
Why?
|
| Animals | 4 | 2019 | 34460 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4684 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 825 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 95 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 492 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2655 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1101 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 683 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 272 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 25 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 622 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 44 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 4762 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 442 | 0.010 |
Why?
|
| Microspheres | 1 | 2005 | 68 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 207 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 252 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2004 | 90 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2003 | 51 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 95 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 119 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 633 | 0.010 |
Why?
|
| Aminocaproic Acid | 1 | 2001 | 4 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 358 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 2001 | 21 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2001 | 78 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2001 | 32 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 141 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 297 | 0.010 |
Why?
|
| Proline | 1 | 2001 | 80 | 0.010 |
Why?
|
| Tranexamic Acid | 1 | 2001 | 31 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 1018 | 0.010 |
Why?
|
| Lysine | 1 | 2001 | 175 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 2000 | 35 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2001 | 118 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2000 | 112 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1319 | 0.010 |
Why?
|
| Normal Distribution | 1 | 1999 | 20 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1626 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 10108 | 0.010 |
Why?
|
| Arginine | 1 | 2001 | 344 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 3629 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 427 | 0.010 |
Why?
|
| Artifacts | 1 | 1999 | 110 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2607 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 13011 | 0.010 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 1996 | 39 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 367 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 366 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 436 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 21008 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 521 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 787 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 2992 | 0.010 |
Why?
|
| Algorithms | 1 | 1999 | 1686 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 2783 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 1503 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 3616 | 0.010 |
Why?
|